Kestra Medical Technologies Ltd. publishes investor presentation on its ASSURE wearable defibrillator system and USD 10 billion U.S. market opportunity

Reuters

Mar 18

Kestra Medical Technologies Ltd. publishes investor presentation on its ASSURE wearable defibrillator system and USD 10 billion U.S. market opportunity

Kestra said it is focused on at-home cardiac care for patients at elevated risk of sudden cardiac arrest, centered on its Cardiac Recovery System anchored by the ASSURE wearable cardioverter defibrillator. The company reported 33,000+ patients protected and 290 million+ covered lives. Kestra also cited a 1-year appropriate therapy rate of 5.4% during the ICD waiting period, and said 73% of sudden cardiac arrests occur at home or a residence. The presentation described a USD 10 billion U.S. total addressable market estimate, including an existing USD 1 billion+ wearable cardioverter defibrillator market. Kestra reported revenue of USD 93 million for FY25 and issued FY26 revenue guidance of USD 59.8 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kestra Medical Technologies Ltd. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620082424"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620082424\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620082424?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 04:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620082424","market":"fut","top_or_hot":-1,"title":"Kestra Medical Technologies Ltd. publishes investor presentation on its ASSURE wearable defibrillator system and USD 10 billion U.S. market opportunity","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kestra Medical Technologies Ltd. publishes investor presentation on its ASSURE wearable defibrillator system and USD 10 billion U.S. market opportunity\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kestra said it is focused on at-home cardiac care for patients at elevated risk of sudden cardiac arrest, centered on its Cardiac Recovery System anchored by the ASSURE wearable cardioverter defibrillator. The company reported 33,000+ patients protected and 290 million+ covered lives. Kestra also cited a 1-year appropriate therapy rate of 5.4% during the ICD waiting period, and said 73% of sudden cardiac arrests occur at home or a residence. The presentation described a USD 10 billion U.S. total addressable market estimate, including an existing USD 1 billion+ wearable cardioverter defibrillator market. Kestra reported revenue of USD 93 million for FY25 and issued FY26 revenue guidance of USD 59.8 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kestra Medical Technologies Ltd. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kestra Medical Technologies Ltd. publishes investor presentation on its ASSURE wearable defibrillator system and USD 10 billion U.S. market opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKestra Medical Technologies Ltd. publishes investor presentation on its ASSURE wearable defibrillator system and USD 10 billion U.S. market opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 04:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kestra Medical Technologies Ltd. publishes investor presentation on its ASSURE wearable defibrillator system and USD 10 billion U.S. market opportunity\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kestra said it is focused on at-home cardiac care for patients at elevated risk of sudden cardiac arrest, centered on its Cardiac Recovery System anchored by the ASSURE wearable cardioverter defibrillator. The company reported 33,000+ patients protected and 290 million+ covered lives. Kestra also cited a 1-year appropriate therapy rate of 5.4% during the ICD waiting period, and said 73% of sudden cardiac arrests occur at home or a residence. The presentation described a USD 10 billion U.S. total addressable market estimate, including an existing USD 1 billion+ wearable cardioverter defibrillator market. Kestra reported revenue of USD 93 million for FY25 and issued FY26 revenue guidance of USD 59.8 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kestra Medical Technologies Ltd. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KMTS","symbol_name":"Kestra Medical Technologies Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL7PsLmL:1","article_id":"2620082424","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620082424","pubTimestamp":1773778672,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kestra Medical Technologies Ltd. publishes investor presentation on its ASSURE wearable defibrillator system and USD 10 billion U.S. market opportunity. Kestra said it is focused on at-home cardiac care for patients at elevated risk of sudden cardiac arrest, centered on its Cardiac Recovery System anchored by the ASSURE wearable cardioverter defibrillator. The company reported 33,000+ patients protected and 290 million+ covered lives. Kestra also cited a 1-year appropriate therapy rate of 5.4% during the ICD waiting period, and said 73% of sudden cardiac arrests occur at home or a residence. The presentation described a USD 10 billion U.S. total addressable market estimate, including an existing USD 1 billion+ wearable cardioverter defibrillator market. Kestra reported revenue of USD 93 million for FY25 and issued FY26 revenue guidance of USD 59.8 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to prov","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KMTS":"Kestra Medical Technologies Inc","BK4082":"医疗保健设备"},"translate_title":"Kestra Medical Technologies Ltd.发布有关其ASSURE可穿戴除颤器系统和100亿美元美国市场机会的投资者介绍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KMTS":0.9},"content_text":"Kestra Medical Technologies Ltd. publishes investor presentation on its ASSURE wearable defibrillator system and USD 10 billion U.S. market opportunity\n    \n\n        Kestra said it is focused on at-home cardiac care for patients at elevated risk of sudden cardiac arrest, centered on its Cardiac Recovery System anchored by the ASSURE wearable cardioverter defibrillator. The company reported 33,000+ patients protected and 290 million+ covered lives. Kestra also cited a 1-year appropriate therapy rate of 5.4% during the ICD waiting period, and said 73% of sudden cardiac arrests occur at home or a residence. The presentation described a USD 10 billion U.S. total addressable market estimate, including an existing USD 1 billion+ wearable cardioverter defibrillator market. Kestra reported revenue of USD 93 million for FY25 and issued FY26 revenue guidance of USD 59.8 million.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kestra Medical Technologies Ltd. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}